Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma
Our findings demonstrate the critical role of RAS-ERK signaling reactivation in driving resistance to BRAF inhibition in glioma and demonstrate the potential utility of adding SHP2 inhibitors to overcome resistance.
Authors
- Calixto‐Hope G. Lucas (ORCID: https://orcid.org/0000-0002-8347-9592)
- Shreya Jagtap (ORCID: https://orcid.org/0000-0001-7864-5587)
- Robyn D. Gartrell (ORCID: https://orcid.org/0000-0003-3287-4223)
- Abiola Abdulrahman Ayanlaja (ORCID: https://orcid.org/0000-0001-7173-0607)
- Karisa C. Schreck (ORCID: https://orcid.org/0000-0001-7181-3269)
- Michael Chang (ORCID: https://orcid.org/0000-0003-4719-0262)
- Christine A. Pratilas (ORCID: https://orcid.org/0000-0002-7116-0605)
- Jean M. Mulcahy Levy (ORCID: https://orcid.org/0000-0002-3022-4246)
- Jiawan Wang (ORCID: https://orcid.org/0000-0002-2137-1826)
- Kriti Lalwani (ORCID: https://orcid.org/0000-0003-0227-4083)
- Maria Ioannou (ORCID: https://orcid.org/0009-0004-8677-7589)
- Yanbo Yang (ORCID: https://orcid.org/0000-0003-1532-9274)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Morgan Adams Foundation (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/noajnl/vdaf170
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- U.S. Department of Defense
- Rally Foundation
- Matthew Larson Foundation for Pediatric Brain Tumors
- Swim Across America
- Children’s Cancer Foundation
- Sidney Kimmel Comprehensive Cancer Center